CPUI
Company Details
Linkedin ID:
chugai-pharmaceutical-co--ltd-
Employees number:
227
Number of followers:
8,148
NAICS:
3254
Industry Type:
Homepage:
chugai-pharm.co.jp
IP Addresses:
0
Company ID:
CHU_8973435
Scan Status:
In-progress
Chugai Pharma USA, Inc. Company CyberSecurity Posture
chugai-pharm.co.jp
Chugai’s strength in R&D and antibody technologies continues on in global efforts for products and services for the benefit of patients. Chugai Pharma USA, Inc. (CPUSA), located in Berkeley Heights, NJ, is a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai). CPUSA supports the planning and execution of global and U.S. clinical programs for Chugai-originated, innovative new drug candidates. Chugai is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs in Chugai’s strategic fields of oncology, bone and joint diseases, and renal diseases as well as other therapeutic areas with serious unmet needs. Chugai develops its products independently from Roche until early Proof-of-Concept (PoC) for worldwide market, including U.S. For late stage clinical development and marketing outside of Japan, South Korea, and Taiwan, Chugai seeks for partnership with Roche, which has the first refusal rights to develop/sell Chugai products, or other third parties. For a list of Chugai’s current research projects please visit: http://www.chugai-pharm.co.jp/english/ir/reports_downloads/pipeline.html
Chugai Pharma USA, Inc. A.I CyberSecurity Scoring
CPUI Risk Score (AI oriented)Between 800 and 849
CPUI
Updated:
- Powered by our proprietary A.I cyber incident model
- Insurance preferes TPRM score to calculate premium
CPUI Global Score (TPRM)XXXX
CPUI
- Instant access to detailed risk factors
- Benchmark vs. industry & size peers
- Vulnerabilities
- Findings
CPUI Company CyberSecurity News & History
Past Incidents
0
Attack Types
0
No data available
CPUI Company Scoring based on AI Models
Cyber Incidents Likelihood 3 - 6 - 9 months
A.I Risk Score Likelihood 3 - 6 - 9 months
Underwriter Stats for CPUI
Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)
No incidents recorded for Chugai Pharma USA, Inc. in 2025.
Incidents vs All-Companies Average (This Year)
No incidents recorded for Chugai Pharma USA, Inc. in 2025.
Incident Types CPUI vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for Chugai Pharma USA, Inc. in 2025.
Incident History — CPUI (X = Date, Y = Severity)
CPUI cyber incidents detection timeline including parent company and subsidiaries
CPUI Company Subsidiaries
Chugai’s strength in R&D and antibody technologies continues on in global efforts for products and services for the benefit of patients. Chugai Pharma USA, Inc. (CPUSA), located in Berkeley Heights, NJ, is a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai). CPUSA supports the planning and execution of global and U.S. clinical programs for Chugai-originated, innovative new drug candidates. Chugai is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs in Chugai’s strategic fields of oncology, bone and joint diseases, and renal diseases as well as other therapeutic areas with serious unmet needs. Chugai develops its products independently from Roche until early Proof-of-Concept (PoC) for worldwide market, including U.S. For late stage clinical development and marketing outside of Japan, South Korea, and Taiwan, Chugai seeks for partnership with Roche, which has the first refusal rights to develop/sell Chugai products, or other third parties. For a list of Chugai’s current research projects please visit: http://www.chugai-pharm.co.jp/english/ir/reports_downloads/pipeline.html
Loading...
CPUI Similar Companies
Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage
MANKIND PHARMA LTD
Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing,
Ipca Laboratories Limited
A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need
Cipla
Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purp
Takeda
We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by list
We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing t
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating wit
Merck Group
This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trad
Alembic Pharmaceuticals Limited
Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrol
.png)
CPUI CyberSecurity News
December 11, 2025 12:31 PM
Secolve report finds OT cybersecurity training falling short across critical infrastructure
Australian OT (operational technology) cybersecurity company Secolve published a report on the precarious cybersecurity of critical...
December 11, 2025 12:15 PM
Savex Technologies and Trellix Announce Nationwide Distribution Partnership for Cybersecurity Solutions in India
Savex Technologies Pvt. Ltd. and Trellix, a global leader in cybersecurity solutions, have entered into a strategic nationwide distribution...
December 11, 2025 12:06 PM
New cybersecurity guidance paves the way for AI in critical infrastructure
Global cybersecurity agencies have issued their first unified guidelines for safely integrating AI into critical infrastructure,...
December 11, 2025 12:04 PM
News - Morton Drug Company discloses cybersecurity breach impacting 40,000 patients
Morton Drug Company, a Wisconsin pharmacy specializing in long-term care services, has disclosed a security incident that compromised the...
December 11, 2025 12:04 PM
AI in medical devices: Why 2026 must be the year cybersecurity catches up
AI is already reshaping patient care – from faster diagnosis and risk scoring to robotic-assisted surgery and continuous monitoring.
December 11, 2025 11:48 AM
Tackling cybersecurity challenges within healthcare
Cybersecurity breaches are commonplace in healthcare settings. Ron Cherry, Director, Cloud Cybersecurity & GRC, Nordic, discusses the...
December 11, 2025 11:32 AM
Complacency in supply chain cybersecurity could be your biggest risk
Every organisation, no matter their resources, can fall victim to a cyberattack, and companies are showing more wishful thinking than...
December 11, 2025 11:30 AM
Automotive Cybersecurity Market to Hit US$ 10,496.7 Million
Press release - Persistence Market Research - Automotive Cybersecurity Market to Hit US$ 10496.7 Million by 2032 as Key Players Such as...
December 11, 2025 11:05 AM
Cybersecurity threats and AI disruptions emerge as top concerns for IT leaders in 2026, finds Veeam study
Veeam Software polled more than 250 senior IT and business decision-makers worldwide to uncover what key trends will shape IT in 2026.
Frequently Asked Questions
Explore insights on cybersecurity incidents, risk posture, and Rankiteo's assessments.
CPUI CyberSecurity History Information
Official Website of Chugai Pharma USA, Inc.
The official website of Chugai Pharma USA, Inc. is http://www.chugai-pharm.co.jp/hc/ss/english/index.html.
Chugai Pharma USA, Inc.’s AI-Generated Cybersecurity Score
According to Rankiteo, Chugai Pharma USA, Inc.’s AI-generated cybersecurity score is 821, reflecting their Good security posture.
How many security badges does Chugai Pharma USA, Inc.’ have ?
According to Rankiteo, Chugai Pharma USA, Inc. currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.
Does Chugai Pharma USA, Inc. have SOC 2 Type 1 certification ?
According to Rankiteo, Chugai Pharma USA, Inc. is not certified under SOC 2 Type 1.
Does Chugai Pharma USA, Inc. have SOC 2 Type 2 certification ?
According to Rankiteo, Chugai Pharma USA, Inc. does not hold a SOC 2 Type 2 certification.
Does Chugai Pharma USA, Inc. comply with GDPR ?
According to Rankiteo, Chugai Pharma USA, Inc. is not listed as GDPR compliant.
Does Chugai Pharma USA, Inc. have PCI DSS certification ?
According to Rankiteo, Chugai Pharma USA, Inc. does not currently maintain PCI DSS compliance.
Does Chugai Pharma USA, Inc. comply with HIPAA ?
According to Rankiteo, Chugai Pharma USA, Inc. is not compliant with HIPAA regulations.
Does Chugai Pharma USA, Inc. have ISO 27001 certification ?
According to Rankiteo,Chugai Pharma USA, Inc. is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.
Industry Classification of Chugai Pharma USA, Inc.
Chugai Pharma USA, Inc. operates primarily in the Pharmaceutical Manufacturing industry.
Number of Employees at Chugai Pharma USA, Inc.
Chugai Pharma USA, Inc. employs approximately 227 people worldwide.
Subsidiaries Owned by Chugai Pharma USA, Inc.
Chugai Pharma USA, Inc. presently has no subsidiaries across any sectors.
Chugai Pharma USA, Inc.’s LinkedIn Followers
Chugai Pharma USA, Inc.’s official LinkedIn profile has approximately 8,148 followers.
NAICS Classification of Chugai Pharma USA, Inc.
Chugai Pharma USA, Inc. is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.
Chugai Pharma USA, Inc.’s Presence on Crunchbase
No, Chugai Pharma USA, Inc. does not have a profile on Crunchbase.
Chugai Pharma USA, Inc.’s Presence on LinkedIn
Yes, Chugai Pharma USA, Inc. maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/chugai-pharmaceutical-co--ltd-.
Cybersecurity Incidents Involving Chugai Pharma USA, Inc.
As of December 11, 2025, Rankiteo reports that Chugai Pharma USA, Inc. has not experienced any cybersecurity incidents.
Number of Peer and Competitor Companies
Chugai Pharma USA, Inc. has an estimated 5,412 peer or competitor companies worldwide.
Chugai Pharma USA, Inc. CyberSecurity History Information
How many cyber incidents has Chugai Pharma USA, Inc. faced ?
Total Incidents: According to Rankiteo, Chugai Pharma USA, Inc. has faced 0 incidents in the past.
What types of cybersecurity incidents have occurred at Chugai Pharma USA, Inc. ?
Incident Types: The types of cybersecurity incidents that have occurred include .
Incident Details
What are the most common types of attacks the company has faced ?
Additional Questions
.png)
Latest Global CVEs (Not Company-Specific)
Description
FreePBX Endpoint Manager is a module for managing telephony endpoints in FreePBX systems. Versions prior to 16.0.96 and 17.0.1 through 17.0.9 have a weak default password. By default, this is a 6 digit numeric value which can be brute forced. (This is the app_password parameter). Depending on local configuration, this password could be the extension, voicemail, user manager, DPMA or EPM phone admin password. This issue is fixed in versions 16.0.96 and 17.0.10.
Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description
Neuron is a PHP framework for creating and orchestrating AI Agents. In versions 2.8.11 and below, the MySQLWriteTool executes arbitrary SQL provided by the caller using PDO::prepare() + execute() without semantic restrictions. This is consistent with the name (“write tool”), but in an LLM/agent context it becomes a high-risk capability: prompt injection or indirect prompt manipulation can cause execution of destructive queries such as DROP TABLE, TRUNCATE, DELETE, ALTER, or privilege-related statements (subject to DB permissions). Deployments that expose an agent with MySQLWriteTool enabled to untrusted input and/or run the tool with a DB user that has broad privileges are impacted. This issue is fixed in version 2.8.12.
Risk Information
cvss3
Base: 9.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:H
Description
Neuron is a PHP framework for creating and orchestrating AI Agents. Versions 2.8.11 and below use MySQLSelectTool, which is vulnerable to Read-Only Bypass. MySQLSelectTool is intended to be a read-only SQL tool (e.g., for LLM agent querying, however, validation based on the first keyword (e.g., SELECT) and a forbidden-keyword list does not block file-writing constructs such as INTO OUTFILE / INTO DUMPFILE. As a result, an attacker who can influence the tool input (e.g., via prompt injection through a public agent endpoint) may write arbitrary files to the DB server if the MySQL/MariaDB account has the FILE privilege and server configuration permits writes to a useful location (e.g., a web-accessible directory). This issue is fixed in version 2.8.12.
Risk Information
cvss3
Base: 8.2
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:N
Description
Okta Java Management SDK facilitates interactions with the Okta management API. In versions 11.0.0 through 20.0.0, race conditions may arise from concurrent requests using the ApiClient class. This could cause a status code or response header from one request’s response to influence another request’s response. This issue is fixed in version 20.0.1.
Risk Information
cvss3
Base: 8.4
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:H/I:H/A:L
Description
The Auth0 Next.js SDK is a library for implementing user authentication in Next.js applications. When using versions 4.11.0 through 4.11.2 and 4.12.0, simultaneous requests on the same client may result in improper lookups in the TokenRequestCache for the request results. This issue is fixed in versions 4.11.2 and 4.12.1.
Risk Information
cvss3
Base: 5.4
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:R/S:U/C:H/I:L/A:N
Access Data Using Our API
Get company history
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?linkedin_id=chugai-pharmaceutical-co--ltd-' -H 'apikey: YOUR_API_KEY_HERE'
RapidWhat Do We Measure ?
Incident
Finding
Grade
Digital Assets
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
These are some of the factors we use to calculate the overall score:
Network Security
Identify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.
SBOM (Software Bill of Materials)
Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.
CMDB (Configuration Management Database)
Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.
Threat Intelligence
Leverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.
